Form 4: Hologic COO Reports RSU Grant, Tax Withholdings

Hologic's Chief Operating Officer, Essex D. Mitchell, reported the acquisition of 47,106 restricted stock units and the disposition of 5,628 shares for tax obligations.

Summary

• Chief Operating Officer Essex D. Mitchell reported transactions involving Hologic Inc. common stock.
• On November 7, 2025, 3,927 shares were disposed of at $74.1 per share to cover tax obligations related to vested performance/restricted stock units.
• On November 10, 2025, 47,106 restricted stock units (RSUs) were acquired. These RSUs vest in equal installments over three years, starting from the grant date.
• On November 11, 2025, an additional 1,701 shares were disposed of at $74.6 per share for tax obligations related to vested performance/restricted stock units.
• Following these transactions, Mitchell beneficially owns 78,952 shares of common stock directly.

Sentiment

Score: 7

Explanation: The grant of a significant number of restricted stock units to a key executive is generally a positive signal, indicating continued commitment and incentive alignment. The dispositions are for tax purposes, which is a neutral, standard event.

Positives

• The acquisition of 47,106 restricted stock units indicates continued long-term incentive alignment between the Chief Operating Officer and shareholder interests.
• The vesting schedule over three years suggests a commitment to retaining key management and incentivizing sustained performance.

Negatives

• The disposition of 5,628 shares (3,927 + 1,701) for tax obligations, while common, represents a reduction in direct share ownership.

Future Outlook

The grant of restricted stock units with a three-year vesting schedule implies an expectation of continued employment and performance from the Chief Operating Officer over that period.

Industry Context

Executive compensation through equity grants like RSUs is a standard practice in the healthcare technology and medical device industry, aligning management incentives with long-term company performance and shareholder value.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) as a significant component of executive compensation is a common practice across the S&P 500 and particularly within the medical technology sector, similar to companies like Intuitive Surgical (ISRG) or Stryker (SYK).
• The three-year vesting schedule for RSUs is typical for executive long-term incentive plans, aiming to retain talent and align interests over a sustained period, consistent with industry benchmarks.
• The disposition of shares to cover tax obligations upon RSU vesting is a standard and expected event for equity compensation, reflecting common tax practices for executives.

Stakeholder Impact

• Shareholders: The RSU grant aligns the COO's interests with long-term shareholder value creation. The tax-related dispositions are a routine part of equity compensation.
• Employees: The compensation structure for a key executive may influence broader compensation strategies and morale.

Next Steps

• The restricted stock units will vest in equal installments on the first three anniversaries of November 10, 2025.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation activities (RSU grant) and associated tax-related share dispositions. It does not provide new fundamental information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The RSU grant is a positive for long-term alignment, but the overall impact on the stock's valuation is neutral. Therefore, a 'hold' recommendation is appropriate, maintaining existing positions based on broader company fundamentals.

Keywords

Hologic Inc, HOLX, Form 4, Insider Trading, Restricted Stock Units, RSU Grant, Executive Compensation, Stock Disposition, Tax Withholding, Essex D Mitchell, Chief Operating Officer